news

Pfizer recalls a further Accuretic tablet batch due to nitrosamines

2
SHARES

Batch number DD4842 of Pfizer’s Accuretic 10/12.5 mg film-coated tablets is being recalled in the UK to the pharmacy and wholesaler level.

black magnifying glass hovering over white tablets

Earlier in the week we reported that Pfizer is voluntarily recalling batches of branded Accuretic (quinapril HCl/hydrochlorothiazide) tablets and two authorised generics to the consumer level in the US due to unacceptable nitrosamine levels. Now, Pfizer is voluntarily recalling another batch of Accuretic tablets due to the identification of the same nitrosamine above the acceptable limit. This recall is to the pharmacy and wholesaler level in the UK.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The Class 2 medicines recall is a precautionary measure after testing revealed levels of the nitrosamine N-nitroso-quinapril above the acceptable limit. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time.

Healthcare professionals are advised to quarantine all remaining stock of the specified Accuretic tablets batch and return them to their supplier using the supplier’s approved process.

Patients should be advised not to stop any treatments without consulting their relevant healthcare professional. The risks of suddenly stopping medication for blood pressure is higher than the potential risk presented by the impurity. Healthcare professionals should advise patients undergoing treatment to discuss any questions or concerns with their prescribing healthcare professional.

The affected batch details are below:

Accuretic 10/12.5 mg film-coated tablets, PL 00057/0518

  • Batch number: DD4842
  • Expiry date: 30 October 2022
  • Pack size: 28
  • First distributed: 6 April 2020

Active Pharmaceutical Ingredients: Quinapril Hydrochloride and Hydrochlorothiazide.

MDR number: MDR 009-03/22

Related organisations

Related drugs

Related diseases & conditions

Share via
Share via